Arbutus Biopharma Corp (NASDAQ: ABUS) is a biopharmaceutical company that focuses on discovering, developing, and commercializing cure for chronic HBV and RNAi therapeutics. The company's lead product candidate is called AB-729, which is a subcutaneously delivered RNAi therapeutic targeting HBV surface antigen (HBsAg). It also has other RNAi candidates that target various indications. Additionally, Arbutus is developing a proprietary oral capsid inhibitor AB-836 that could complement AB-729 in combination therapies. Arbutus also has a robust proprietary lipid nanoparticle (LNP) platform technology for the delivery of RNAi therapeutics.
Arbutus was founded in 2008 and is headquartered in Warminster, Pennsylvania.
Arbutus Biopharma Corp (NASDAQ: ABUS) is a biopharmaceutical company that focuses on discovering, developing, and commercializing cure for chronic HBV and RNAi therapeutics. The company's lead product candidate is called AB-729, which is a subcutaneously delivered RNAi therapeutic targeting HBV surface antigen (HBsAg). It also has other RNAi candidates that target various indications. Additionally, Arbutus is developing a proprietary oral capsid inhibitor AB-836 that could complement AB-729 in combination therapies. Arbutus also has a robust proprietary lipid nanoparticle (LNP) platform technology for the delivery of RNAi therapeutics.